Tipp

2. Stellungnahme der Netzhautkommission der ÖOG zur transskleralen Anwendung von Wachstumhemmern

Zeitschrift:: Spektrum der Augenheilkunde > Ausgabe 4/2013

Autor:: a.Univ.Prof.Dr. Michael Stur

» Jetzt Zugang zum Volltext erhalten

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Scott AW, Bressler SB. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2013;24(3):190–6 (Epub 2013/03/16). PubMedCrossRef

Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411 (Epub 2012/05/15). PubMedCrossRef

Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48 (Epub 2012/10/23). PubMedCrossRef

Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–98 (Epub 2012/05/05). PubMedCrossRef

Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266–71 (Epub 2013/01/08). PubMedCrossRef

Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115(12):2199–205 (Epub 2008/10/22). PubMedCrossRef

Avgikos KN, Horgan SE, Sivaraj RR, et al. Tachyphylaxis and bevacizumab. Ophthalmology. 2009;116(9):1831–2 (author reply 2. Epub 2009/09/05). PubMedCrossRef

Falavarjani KG, Modarres M. Bevacizumab tachyphylaxis. Ophthalmology. 2009;116(5):1016–7 (author reply 7. Epub 2009/05/05). PubMedCrossRef

Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (Philadelphia, Pa). 2009;29(6):723–31 (Epub 2009/06/12). CrossRef

10.

Ziemssen F, Neuhann IM, Voelker M. Tachyphylaxis and bevacizumab. Ophthalmology. 2009;116(8):1591–2 (author reply 2–3. Epub 2009/08/05). PubMedCrossRef

11.

Forooghian F, Chew EY, Meyerle CB, et al. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol. 2011;89(2):e206–7 (Epub 2009/11/11). PubMedCrossRef

12.

Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1–2 (Epub 2011/12/14). PubMedCrossRef

13.

Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96(1):14–20 (Epub 2011/07/28). PubMedCrossRef

14.

Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina (Philadelphia, Pa). 2013 (Epub 2013/04/04).

15.

Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (London, England). 2013;27(5):663–8 (Epub 2013/04/06). CrossRef

16.

Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013 (Epub 2013/05/15).

17.

Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013 (Epub 2013/05/15).

18.

Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013 (Epub 2013/05/28).

19.

Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina (Philadelphia, Pa). 2012;32(3):434–57 (Epub 2012/03/01).

20.

Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013;120(2):349–54 (Epub 2012/11/08). PubMedCrossRef

21.

Jutley G, Shona OA, Leen RC, et al. Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol. 2012;130(11):1466–70 (Epub 2012/11/13). PubMedCrossRef

Titel: 2. Stellungnahme der Netzhautkommission der ÖOG zur transskleralen Anwendung von Wachstumhemmern
Autor:: a.Univ.Prof.Dr. Michael Stur
Publikationsdatum: 01.08.2013
DOI: https://doi.org/10.1007/s00717-013-0180-7
Verlag: Springer Vienna
Zeitschrift: Spektrum der Augenheilkunde
Ausgabe 4/2013
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Editorial

Chirurgische Therapie einer großen Dermoidzyste mit Orbitabeteiligung

Hyperhomocysteinämie bei Patienten/innen mit retinalen arteriellen Verschlüssen – gibt es Evidenz für einen Benefit einer therapeutischen Homocysteinsenkung?

Erratum zu: Phakozeitenvergleich zwischen Geuder G-24310 PEP 2,2 mm und G-24055 Phakospitzen

Trübe Aussichten – wenn die Kornea zum Problemfall wird

Fortbildungsveranstaltungen